The global Medical Marijuana Market is expected to witness a CAGR of 14.8% and reach US$ 76.5 Bn by the year 2021-2031. With the way in which healthcare data gets accumulated these days (which could be inclusive of medical IoT solutions, DICOM files, and patient records), ultra-modern platforms like data fabrics are in the offing, so that distributed and structured data could be well-managed. This would be healthcare industry’s situation in the upcoming period.
According to a recent study by Persistence Market Research, the global medical marijuana market is expected to witness high growth at a CAGR of around 14.8% and reach a valuation of US$ 76.5 Bn by 2031.
Medical marijuana is derived from the Cannabis sativa plant. The three major active compounds of the plant are tetrahydrocannabinol, cannabidiol, and cannabinol. Medical marijuana has various applications in the healthcare and therapeutic field, including treatment or managing pain, treating nausea, muscle spasms, managing anxiety, multiple sclerosis, low appetite, sleep problems, and many others.
Other factors driving demand for medical marijuana include the ability to manage or treat insomnia and epilepsy. According to healthcare specialists, medical marijuana is an effective option to manage sleep-related problems because it restores a person’s natural sleep cycle that changes due to today’s modern lifestyle.
Medical marijuana is also known for its strong anti-inflammatory properties. It can treat inflammation from arthritis as well as degenerative changes in the lumbar, cervical or thoracic spine. Many patients use marijuana to treat their pain caused due to inflammation.
Pharmaceutical companies are focused on getting approvals from different government authorities for the use of medical marijuana for treatment purposes.
In September 2019, GW Pharmaceuticals received approval from European the Commission for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy.
In October 2021, Canopy Growth Corporation announced a plan to acquire Wana Entity, which is a leading cannabis edibles brand in North America.
In August 2020, MedReleaf Corp. and BioPharma Services Inc. announced their agreement to conduct clinical research for cannabis and cannabis-derived products.
The extract form of marijuana is widely used in a wide range of applications in the therapeutic field as compared to dried flowers.
The pain management segment enjoys a high market share of 48.8%, indicating high demand for medical marijuana in pain management procedures.
77.6% market share in the distribution channel segment is held by retail pharmacies, because the market is closely regulated by government authorities.
The North America market is set to grow 5X by 2031.
“Increasing prevalence of chronic pain and epilepsy and legalization of medical marijuana in developing countries are major factors driving demand,” says a Persistence Market Research analyst.
Who is Winning?
Leading medical marijuana manufacturers are constantly working toward expanding their product portfolios and market presence through key strategies such as product approvals and distribution and collaboration agreements.
GW Pharmaceuticals received approval from Australian Therapeutic Goods Administration (TGA) for EPIDYOLEX® (cannabidiol) for the treatment epilepsy (2020). The FDA approved EPIDIOLEX® (cannabidiol) oral solution to treat seizures associated with tuberous sclerosis complex.
Tilray signed a distribution agreement with great north distributors for adult-use cannabis sales across Canada.
Want More Insights?
Persistence Market Research brings a comprehensive research report on forecasted revenue growth at global, regional, and country levels, and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The global medical marijuana market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
The study provides compelling insights into the medical marijuana market. The market is segmented into four parts based on product (dried flowers and extract form), application (pain management, seizure, and others), distribution channel (retail pharmacies and e-Commerce), and seven major regions.
The global outsourced clinical trials & formulation market is set to record a market value of US$ 14.1 Bn in 2022, and expand at a CAGR of 6.7% to reach a market valuation of US$ 19.6 Bn by the end of 2027.
Cell-free protein expression demand is set to be valued at around US$ 409 Mn by the end of 2032.
About us:
PersistenceMarketResearch is an esteemed company with a reputation of serving clients across domains of information technology (IT), healthcare, and chemicals. Our analysts undertake painstaking primary and secondary research to provide a seamless report with a 360 degree perspective. Data is compared against rep/uted organizations, trustworthy databases, and international surveys for producing impeccable reports backed with graphical and statistical information.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
